283 related articles for article (PubMed ID: 28264853)
1. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.
Zhou J; Ledesma KR; Chang KT; Abodakpi H; Gao S; Tam VH
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264853
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
Koomanachai P; Kim A; Nicolau DP
J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
[TBL] [Abstract][Full Text] [Related]
3. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of Minocycline against
Tarazi Z; Sabet M; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30397059
[TBL] [Abstract][Full Text] [Related]
5. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
[TBL] [Abstract][Full Text] [Related]
6. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.
Lin YW; Zhou QT; Han ML; Chen K; Onufrak NJ; Wang J; Turnidge JD; Howden BP; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29229637
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Shigemi A; Umezaki Y; Nakamura K; Ueno K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Jun; 43(6):547-52. PubMed ID: 24796218
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection.
Alfouzan WA; Noel AR; Bowker KE; Attwood MLG; Tomaselli SG; MacGowan AP
Int J Antimicrob Agents; 2017 Dec; 50(6):715-717. PubMed ID: 28705678
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia.
Ku NS; Lee SH; Lim YS; Choi H; Ahn JY; Jeong SJ; Shin SJ; Choi JY; Choi YH; Yeom JS; Yong D; Song YG; Kim JM
Sci Rep; 2019 Nov; 9(1):17127. PubMed ID: 31748527
[TBL] [Abstract][Full Text] [Related]
11. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
Dudhani RV; Turnidge JD; Nation RL; Li J
J Antimicrob Chemother; 2010 Sep; 65(9):1984-90. PubMed ID: 20573659
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs.
Crandon JL; Kim A; Nicolau DP
J Antimicrob Chemother; 2009 Oct; 64(4):837-9. PubMed ID: 19696049
[TBL] [Abstract][Full Text] [Related]
13. In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.
Yang YS; Lee Y; Tseng KC; Huang WC; Chuang MF; Kuo SC; Lauderdale TL; Chen TL
Antimicrob Agents Chemother; 2016 Jul; 60(7):4047-54. PubMed ID: 27114274
[TBL] [Abstract][Full Text] [Related]
14. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.
Bowers DR; Cao H; Zhou J; Ledesma KR; Sun D; Lomovskaya O; Tam VH
Antimicrob Agents Chemother; 2015 May; 59(5):2720-5. PubMed ID: 25712362
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
16. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
Morfin-Otero R; Dowzicky MJ
Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
[TBL] [Abstract][Full Text] [Related]
17. Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model.
Higuchi S; Kurosaka Y; Uoyama S; Yoshida K; Chiba M; Ishii C; Fujikawa K; Karibe Y; Hoshino K
J Infect Chemother; 2014 May; 20(5):312-6. PubMed ID: 24594453
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
[TBL] [Abstract][Full Text] [Related]
19. Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection.
Huang Y; Wiradharma N; Xu K; Ji Z; Bi S; Li L; Yang YY; Fan W
Biomaterials; 2012 Dec; 33(34):8841-7. PubMed ID: 22925814
[TBL] [Abstract][Full Text] [Related]
20. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options.
Castanheira M; Mendes RE; Jones RN
Clin Infect Dis; 2014 Dec; 59 Suppl 6():S367-73. PubMed ID: 25371512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
